Omega Funds

Callio Therapeutics specializes in the development of advanced antibody-drug conjugates (ADCs) for cancer treatment. Their focus is on creating multi-payload ADCs, which allow for the targeted delivery of drug combinations to tumor cells, potentially maximizing therapeutic benefits and improving patient outcomes.

Windward Bio is a clinical-stage biopharmaceutical company dedicated to enhancing outcomes for patients with advanced immunological diseases, focusing on severe respiratory conditions. The company is advancing a fully human monoclonal antibody targeting thymic stromal lymphopoietin (TSLP) into phase 2 clinical trials. This antibody, administered subcutaneously, potently binds to the TSLP ligand, extending its half-life and silencing its effector functions. Windward Bio is also developing innovative bispecific programs for other immunological disorders, led by a team of experienced biopharmaceutical executives aiming to address significant unmet medical needs in this field.

Founded in 2020 and headquartered in Boston, Massachusetts, Scorpion Therapeutics is a clinical-stage biotechnology company specializing in precision oncology. It develops targeted small-molecule drugs to treat cancer by focusing on three areas: therapies against known oncogenes, agents for currently undruggable targets, and drugs for new targets.

Endeavor BioMedicines is a clinical-stage company based in Solana Beach, California, founded in 2018. The company is dedicated to developing innovative treatments that address the underlying causes of pulmonary fibrosis, particularly idiopathic pulmonary fibrosis (IPF). Endeavor BioMedicines is focused on creating a small-molecule inhibitor that has the potential to not only halt the progression of IPF but also to reverse its effects. By concentrating on these advancements, the company aims to enable healthcare professionals to provide more precise treatments for terminal conditions, ultimately improving patient outcomes and enhancing quality of life.

Alumis is a clinical-stage biopharmaceutical company specializing in precision medicines for autoimmune disorders. It leverages its proprietary precision data analytics platform and expertise in immunology to develop targeted therapies that significantly improve patients' lives.

Chroma Medicine is a genomic medicine company founded in 2021 and based in Cambridge, Massachusetts, specializing in epigenetic editing. The company is pioneering a new class of genomic therapies aimed at revolutionizing the treatment of genetically driven diseases. By utilizing epigenetics, which is the natural mechanism for gene regulation, Chroma Medicine develops programmable epigenetic editors that target specific genes and modulate chromatin conformation. This innovative approach enables healthcare providers to achieve precise control of gene expression, offering a promising therapeutic option for conditions linked to genetic anomalies.

CDR-Life is a Zurich-based biotech company that develops therapeutic antibody fragments with a focus on immuno-oncology and ophthalmology. It develops highly selective immunotherapies against cancer and autoimmune diseases, leveraging technology to create MHC-specific antibodies that target intracellular tumor antigens for targeted treatment. Its facilities are located in the Bio-Technopark Schlieren-Zurich, Switzerland.

Endeavor BioMedicines is a clinical-stage company based in Solana Beach, California, founded in 2018. The company is dedicated to developing innovative treatments that address the underlying causes of pulmonary fibrosis, particularly idiopathic pulmonary fibrosis (IPF). Endeavor BioMedicines is focused on creating a small-molecule inhibitor that has the potential to not only halt the progression of IPF but also to reverse its effects. By concentrating on these advancements, the company aims to enable healthcare professionals to provide more precise treatments for terminal conditions, ultimately improving patient outcomes and enhancing quality of life.

Chroma Medicine is a genomic medicine company founded in 2021 and based in Cambridge, Massachusetts, specializing in epigenetic editing. The company is pioneering a new class of genomic therapies aimed at revolutionizing the treatment of genetically driven diseases. By utilizing epigenetics, which is the natural mechanism for gene regulation, Chroma Medicine develops programmable epigenetic editors that target specific genes and modulate chromatin conformation. This innovative approach enables healthcare providers to achieve precise control of gene expression, offering a promising therapeutic option for conditions linked to genetic anomalies.

Artios Pharma Limited is a biotechnology company based in Cambridge, United Kingdom, that specializes in developing innovative cancer treatments targeting DNA damage response (DDR) pathways. Founded in 2016, the company is dedicated to creating first-in-class therapies that selectively kill cancer cells by exploiting their reliance on DDR mechanisms. Artios’ product pipeline includes a range of promising candidates, such as a therapy that targets DNA polymerase theta, a protein involved in DNA repair processes, and another program focusing on a novel DDR target. The company collaborates with prominent research organizations, including Cancer Research Technology, to enhance its development efforts and leverage expertise in DNA repair. Artios is led by a skilled team with extensive experience in drug discovery, positioning it to advance its next-generation DDR programs and contribute significantly to the field of cancer treatment.

Synthekine Inc. is a biotechnology company based in Menlo Park, California, specializing in the development of engineered cytokine therapies and immunotherapies aimed at treating cancer and autoimmune disorders. Founded in 2018, Synthekine utilizes advanced platform technologies, including engineered partial agonists and orthogonal cell therapies, to enhance the efficacy of cytokines while minimizing their toxic side effects. The company's innovative Synthekine Platform employs surrogate agonists instead of traditional mutant cytokines to create selective immunotherapies. Its product pipeline features candidates such as STK-009, an orthogonal ligand paired with SYNCAR-001, an orthogonal receptor-modified CAR-T therapy targeting CD-19. Additionally, Synthekine is developing STK-012, partial agonists of IL-2, and other novel immunotherapies that integrate cytokine receptors to initiate new signaling pathways without relying on wild-type cytokines.

Invivyd is a commercial-stage biopharmaceutical company dedicated to developing and commercializing antibody-based therapies aimed at protecting individuals from serious viral infectious diseases, particularly those with pandemic potential. The company focuses on innovative solutions that surpass the natural limits of immunity, starting with its lead product candidates for SARS-CoV-2. Notable among these candidates are ADG20, designed for the treatment and prevention of COVID-19, and VYD222, a monoclonal antibody optimized for enhanced potency and durability of protection. Invivyd's mission centers on delivering effective, long-lasting therapies to safeguard vulnerable populations from the severe repercussions of ongoing viral threats.

Theseus Pharmaceuticals is a biopharmaceutical company dedicated to enhancing the lives of cancer patients through the development of targeted therapies. The company focuses on discovering and commercializing innovative treatments that specifically address drug resistance mutations in critical driver oncogenes, which are genes that, when mutated, contribute to cancer progression. By leveraging advanced technology, Theseus Pharmaceuticals aims to transform cancer care and improve patient outcomes.

Icosavax develops virus-like particle (VLP) vaccines using its proprietary computational design platform. Its primary focus is creating vaccines for life-threatening respiratory diseases, with current candidates targeting respiratory syncytial virus (RSV), human metapneumovirus (hMPV), and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Founded in 2017, the company aims to discover, develop, and commercialize vaccines against infectious diseases.

Endeavor BioMedicines is a clinical-stage company based in Solana Beach, California, founded in 2018. The company is dedicated to developing innovative treatments that address the underlying causes of pulmonary fibrosis, particularly idiopathic pulmonary fibrosis (IPF). Endeavor BioMedicines is focused on creating a small-molecule inhibitor that has the potential to not only halt the progression of IPF but also to reverse its effects. By concentrating on these advancements, the company aims to enable healthcare professionals to provide more precise treatments for terminal conditions, ultimately improving patient outcomes and enhancing quality of life.

Founded in 2020 and headquartered in Boston, Massachusetts, Scorpion Therapeutics is a clinical-stage biotechnology company specializing in precision oncology. It develops targeted small-molecule drugs to treat cancer by focusing on three areas: therapies against known oncogenes, agents for currently undruggable targets, and drugs for new targets.

Syros Pharmaceuticals, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, that specializes in developing innovative treatments for cancer and monogenic diseases through gene control medicines. The company is advancing its lead product candidates, including SY-1425, a selective retinoic acid receptor alpha agonist currently in Phase II clinical trials for specific patient populations with acute myeloid leukemia and myelodysplastic syndrome, and SY-5609, a cyclin-dependent kinase 7 inhibitor under investigation in a Phase I clinical trial for advanced solid tumors. Syros is also engaged in collaborative research, including a partnership with Incyte Corporation aimed at identifying therapeutic targets for myeloproliferative neoplasms and a licensing agreement with TMRC Co. Ltd. for the development of tamibarotene. With a focus on mapping gene regulatory circuits, Syros leverages its proprietary platform and expertise to address significant unmet medical needs in oncology. Founded in 2011, the company aims to establish new standards of care for patients with hematologic malignancies.

Imago BioSciences, Inc. is a clinical-stage biotechnology company based in Redwood City, California, founded in 2012. The company specializes in developing novel small molecule therapeutics aimed at treating hematologic diseases, including myelodysplastic syndromes, acute myelogenous leukemia, and other conditions associated with bone marrow failure. Central to its research is the enzyme lysine-specific demethylase 1 (LSD1), which is involved in the regulation of blood cell production. Imago BioSciences is focused on translating advanced scientific insights into transformative therapies that can alter the course of disease, thereby enhancing the quality and longevity of life for patients. Its lead product candidate, Bomedemstat, is an orally administered LSD1 inhibitor currently under evaluation for its potential to modify disease progression in patients with myeloproliferative neoplasms, a group of chronic bone marrow cancers.

Invivyd is a commercial-stage biopharmaceutical company dedicated to developing and commercializing antibody-based therapies aimed at protecting individuals from serious viral infectious diseases, particularly those with pandemic potential. The company focuses on innovative solutions that surpass the natural limits of immunity, starting with its lead product candidates for SARS-CoV-2. Notable among these candidates are ADG20, designed for the treatment and prevention of COVID-19, and VYD222, a monoclonal antibody optimized for enhanced potency and durability of protection. Invivyd's mission centers on delivering effective, long-lasting therapies to safeguard vulnerable populations from the severe repercussions of ongoing viral threats.

Founded in 2020 and headquartered in Boston, Massachusetts, Scorpion Therapeutics is a clinical-stage biotechnology company specializing in precision oncology. It develops targeted small-molecule drugs to treat cancer by focusing on three areas: therapies against known oncogenes, agents for currently undruggable targets, and drugs for new targets.

Nuvation Bio is a global biopharmaceutical company dedicated to developing innovative therapies for oncology, focusing on patients with difficult-to-treat cancers where conventional treatments have proven ineffective.

Chord Therapeutics SA is a biotechnology company based in Geneva, Switzerland, founded in 2014. It focuses on developing innovative drug therapies for rare and severely disabling diseases, specifically targeting conditions such as neuromyelitis optica spectrum disorders and myasthenia gravis. The company is advancing its lead drug candidate, CRD1, which has received orphan drug designation to address these critical health challenges. Chord Therapeutics is dedicated to repurposing small molecule drugs to provide effective treatments that can significantly improve the quality of life for patients suffering from these rare neurological disorders.

Kronos Bio, Inc. is a clinical-stage biopharmaceutical company based in San Mateo, California, focused on the discovery and development of innovative cancer therapeutics. Established in 2017, the company aims to address historically challenging cancer targets through precision medicine. Its primary product candidates include entospletinib, a selective inhibitor of spleen tyrosine kinase intended for acute myeloid leukemia patients, and KB-0742, an orally bioavailable inhibitor of cyclin-dependent kinase 9 for treating MYC-amplified solid tumors. Kronos Bio employs advanced technologies, such as high-throughput small-molecule microarrays and targeted protein degradation, to identify potent and selective compounds that target dysregulated transcription factors and other key drivers of oncogenic signaling.

Founded in 2018, Sana Biotechnology focuses on creating and delivering engineered cells as medicine for patients. The company aims to reprogram cells in the body or replace damaged ones to treat a broad range of diseases, with a pipeline including SC291, SC262, SC255, UP421, and other candidates across therapeutic areas like oncology, diabetes, autoimmune disorders, and CNS.

FoRx Therapeutics is a biotechnology company focused on developing cancer therapies by targeting DNA replication stress. It seeks to drug key molecular targets involved in replication stress to create targeted anticancer drugs. Founded in 2019 and based in Basel, Switzerland, the company emphasizes a novel approach by targeting DNA replication stress pathways activated in cancer cells, with the goal of delivering first-in-class therapies that address the underlying mechanisms of tumor growth.

Spruce Biosciences is a biopharmaceutical company focused on developing therapies for rare endocrine disorders. Its pipeline includes tildacerfont for classic congenital adrenal hyperplasia in adults and children, with ongoing clinical development, and Tralesinidase Alfa in its portfolio. The company collaborates with Eli Lilly to research, develop, and commercialize compounds. Founded in 2014, Spruce Biosciences is headquartered in Daly City, California, and aims to deliver meaningful therapies for patients with rare endocrine diseases.

IFM Therapeutics is a biotechnology company focused on developing small-molecule medicines that modulate the innate immune system to treat inflammatory and autoimmune diseases and cancer. Its approach combines in-house discovery with collaborations to target novel components of innate immunity. The company operates through subsidiaries and affiliates, including IFM Due, which concentrates on antagonists of the cGAS/STING pathway for inflammation, neuroinflammation, autoimmunity, and cancer, and IFM Discovery, an incubator pursuing a portfolio of genetically validated targets as next-generation therapies for inflammation, neuroinflammation, autoimmunity, and fibrosis. By designing small molecules that precisely engage innate immune targets, IFM Therapeutics aims to improve patient immune responses and address difficult therapeutic areas.

Nuvation Bio is a global biopharmaceutical company dedicated to developing innovative therapies for oncology, focusing on patients with difficult-to-treat cancers where conventional treatments have proven ineffective.

Kronos Bio, Inc. is a clinical-stage biopharmaceutical company based in San Mateo, California, focused on the discovery and development of innovative cancer therapeutics. Established in 2017, the company aims to address historically challenging cancer targets through precision medicine. Its primary product candidates include entospletinib, a selective inhibitor of spleen tyrosine kinase intended for acute myeloid leukemia patients, and KB-0742, an orally bioavailable inhibitor of cyclin-dependent kinase 9 for treating MYC-amplified solid tumors. Kronos Bio employs advanced technologies, such as high-throughput small-molecule microarrays and targeted protein degradation, to identify potent and selective compounds that target dysregulated transcription factors and other key drivers of oncogenic signaling.

Imago BioSciences, Inc. is a clinical-stage biotechnology company based in Redwood City, California, founded in 2012. The company specializes in developing novel small molecule therapeutics aimed at treating hematologic diseases, including myelodysplastic syndromes, acute myelogenous leukemia, and other conditions associated with bone marrow failure. Central to its research is the enzyme lysine-specific demethylase 1 (LSD1), which is involved in the regulation of blood cell production. Imago BioSciences is focused on translating advanced scientific insights into transformative therapies that can alter the course of disease, thereby enhancing the quality and longevity of life for patients. Its lead product candidate, Bomedemstat, is an orally administered LSD1 inhibitor currently under evaluation for its potential to modify disease progression in patients with myeloproliferative neoplasms, a group of chronic bone marrow cancers.

First Wave Bio, Inc. is a clinical-stage biotechnology company based in Ann Arbor, Michigan, that focuses on developing gut-targeted small molecules for the treatment of inflammatory bowel disease (IBD) and other serious conditions. Established in 2015, the company aims to provide effective and safe medical solutions to address the unmet needs of IBD patients. Its primary innovation is a gut-restricted small molecule designed for oral or rectal administration, specifically targeting ulcerative colitis and enhancing accessibility and affordability of treatment options for patients suffering from this condition.

Andrew Alliance is a Swiss robotics company that designs and commercializes automated liquid-handling solutions for the life sciences sector. The company offers a suite of hardware and software tools, including OneLab, a graphical interface to design liquid-handling workflows; Andrew+, a pipetting robot compatible with conventional electronic pipettes; Pipette, a cloud-enabled device to improve ergonomics and traceability; and Andrew, a portable liquid-handling robot that can operate unattended with manual pipettes. It also provides Andrew Assistant, a protocol-design software to create, verify, and document biology protocols that require quantitative liquid handling. Products are assembled and tested in Switzerland, with service and support based in Geneva and an office in Boston, and are sold directly and through distributor partners internationally. Founded in 2011, Andrew Alliance is an independent Swiss company that combines robotics, vision and software to enable researchers to perform precise, repeatable liquid-handling operations more efficiently, aiming to enhance accuracy and throughput in laboratory workflows.

Kronos Bio, Inc. is a clinical-stage biopharmaceutical company based in San Mateo, California, focused on the discovery and development of innovative cancer therapeutics. Established in 2017, the company aims to address historically challenging cancer targets through precision medicine. Its primary product candidates include entospletinib, a selective inhibitor of spleen tyrosine kinase intended for acute myeloid leukemia patients, and KB-0742, an orally bioavailable inhibitor of cyclin-dependent kinase 9 for treating MYC-amplified solid tumors. Kronos Bio employs advanced technologies, such as high-throughput small-molecule microarrays and targeted protein degradation, to identify potent and selective compounds that target dysregulated transcription factors and other key drivers of oncogenic signaling.

Senti Biosciences is a biotechnology company focused on synthetic biology. It develops gene circuit platforms to engineer therapeutics, with a focus on improving precision and control in cancer treatments.

Translate Bio, Inc. is a clinical-stage biotechnology company focused on developing messenger RNA (mRNA) therapeutics aimed at addressing diseases linked to protein or gene dysfunction. Founded in 2011 and headquartered in Lexington, Massachusetts, the company is advancing its lead candidates, MRT5005 and MRT5201. MRT5005 is currently undergoing Phase I/II clinical trials for the treatment of cystic fibrosis, while MRT5201 is being developed for ornithine transcarbamylase deficiency. Translate Bio was previously known as RaNA Therapeutics, Inc. before rebranding in June 2017. The company specializes in innovative therapies for rare diseases, leveraging the potential of RNA-based medicine.

Replimune Group is a clinical-stage biotechnology company developing oncolytic immunotherapies for cancer treatment using its proprietary Immulytic platform. This platform aims to maximize systemic immune activation against tumor antigens through viral-mediated immunogenic tumor cell killing and delivery of optimal immune-activating proteins.

Kezar Life Sciences, Inc. is a clinical-stage biotechnology company based in South San Francisco, California, focused on the discovery and development of small molecule therapeutics aimed at addressing unmet medical needs in autoimmunity and cancer. The company's lead product candidate, KZR-616, is a selective immunoproteasome inhibitor currently undergoing Phase 2 clinical trials for five autoimmune conditions, including lupus nephritis and autoimmune hemolytic anemia, as well as Phase 1b/2 trials in systemic lupus erythematosus. In addition to KZR-616, Kezar is developing KZR-261, which targets oncology and autoimmune indications. Founded in 2015, the company leverages innovative research in protein homeostasis and has established a pipeline of potential therapies to advance treatment options for patients.

Translate Bio, Inc. is a clinical-stage biotechnology company focused on developing messenger RNA (mRNA) therapeutics aimed at addressing diseases linked to protein or gene dysfunction. Founded in 2011 and headquartered in Lexington, Massachusetts, the company is advancing its lead candidates, MRT5005 and MRT5201. MRT5005 is currently undergoing Phase I/II clinical trials for the treatment of cystic fibrosis, while MRT5201 is being developed for ornithine transcarbamylase deficiency. Translate Bio was previously known as RaNA Therapeutics, Inc. before rebranding in June 2017. The company specializes in innovative therapies for rare diseases, leveraging the potential of RNA-based medicine.

Replimune Group is a clinical-stage biotechnology company developing oncolytic immunotherapies for cancer treatment using its proprietary Immulytic platform. This platform aims to maximize systemic immune activation against tumor antigens through viral-mediated immunogenic tumor cell killing and delivery of optimal immune-activating proteins.

Editas Medicine is a clinical-stage biotechnology company based in Cambridge, Massachusetts, with an additional site in Boulder, Colorado. Founded in 2013, the company focuses on the discovery and development of genome editing therapeutics, primarily utilizing its proprietary CRISPR/Cas9 technology. This innovative platform enables precise molecular modifications at the genetic level, with the aim of treating a wide array of serious diseases by addressing their underlying causes. Editas Medicine has established a strong intellectual property portfolio, which includes numerous patents related to foundational genome editing technologies and advancements that facilitate the translation of research into viable human therapeutics. The company's mission is to pioneer transformative genomic medicines that can significantly improve patient outcomes across various genetic disorders.

Translate Bio, Inc. is a clinical-stage biotechnology company focused on developing messenger RNA (mRNA) therapeutics aimed at addressing diseases linked to protein or gene dysfunction. Founded in 2011 and headquartered in Lexington, Massachusetts, the company is advancing its lead candidates, MRT5005 and MRT5201. MRT5005 is currently undergoing Phase I/II clinical trials for the treatment of cystic fibrosis, while MRT5201 is being developed for ornithine transcarbamylase deficiency. Translate Bio was previously known as RaNA Therapeutics, Inc. before rebranding in June 2017. The company specializes in innovative therapies for rare diseases, leveraging the potential of RNA-based medicine.

Kezar Life Sciences, Inc. is a clinical-stage biotechnology company based in South San Francisco, California, focused on the discovery and development of small molecule therapeutics aimed at addressing unmet medical needs in autoimmunity and cancer. The company's lead product candidate, KZR-616, is a selective immunoproteasome inhibitor currently undergoing Phase 2 clinical trials for five autoimmune conditions, including lupus nephritis and autoimmune hemolytic anemia, as well as Phase 1b/2 trials in systemic lupus erythematosus. In addition to KZR-616, Kezar is developing KZR-261, which targets oncology and autoimmune indications. Founded in 2015, the company leverages innovative research in protein homeostasis and has established a pipeline of potential therapies to advance treatment options for patients.

Replimune Group is a clinical-stage biotechnology company developing oncolytic immunotherapies for cancer treatment using its proprietary Immulytic platform. This platform aims to maximize systemic immune activation against tumor antigens through viral-mediated immunogenic tumor cell killing and delivery of optimal immune-activating proteins.

Andrew Alliance is a Swiss robotics company that designs and commercializes automated liquid-handling solutions for the life sciences sector. The company offers a suite of hardware and software tools, including OneLab, a graphical interface to design liquid-handling workflows; Andrew+, a pipetting robot compatible with conventional electronic pipettes; Pipette, a cloud-enabled device to improve ergonomics and traceability; and Andrew, a portable liquid-handling robot that can operate unattended with manual pipettes. It also provides Andrew Assistant, a protocol-design software to create, verify, and document biology protocols that require quantitative liquid handling. Products are assembled and tested in Switzerland, with service and support based in Geneva and an office in Boston, and are sold directly and through distributor partners internationally. Founded in 2011, Andrew Alliance is an independent Swiss company that combines robotics, vision and software to enable researchers to perform precise, repeatable liquid-handling operations more efficiently, aiming to enhance accuracy and throughput in laboratory workflows.

BioSilta Ltd. is a biotechnology company based in St. Ives, United Kingdom, that specializes in the development of reagent-based microbial growth systems. Established in 2014, the company offers innovative products such as the EnPresso B series, which enhances recombinant protein yields from bacterial cultures, and EnPresso Y Defined, a tablet-based growth system for yeast cultures. BioSilta utilizes its proprietary EnBase technology platform to significantly improve the yield of high-quality biomolecules from microbial cultures compared to traditional growth media. The company also provides essential accessories, including flasks, seals, and culture plates, to support its growth systems.

Translate Bio, Inc. is a clinical-stage biotechnology company focused on developing messenger RNA (mRNA) therapeutics aimed at addressing diseases linked to protein or gene dysfunction. Founded in 2011 and headquartered in Lexington, Massachusetts, the company is advancing its lead candidates, MRT5005 and MRT5201. MRT5005 is currently undergoing Phase I/II clinical trials for the treatment of cystic fibrosis, while MRT5201 is being developed for ornithine transcarbamylase deficiency. Translate Bio was previously known as RaNA Therapeutics, Inc. before rebranding in June 2017. The company specializes in innovative therapies for rare diseases, leveraging the potential of RNA-based medicine.

Oxagen Limited is a biopharmaceutical company based in London, United Kingdom, focused on developing and commercializing anti-inflammatory medicines to treat asthma and other chronic allergic conditions. The company specializes in small molecule drugs that target the CRTH2 receptor, which plays a key role in initiating and maintaining allergic responses. Oxagen's pipeline includes OC000459, an oral CRTH2 antagonist designed for eosinophilic asthma and allergic rhinoconjunctivitis. Additionally, the company addresses various inflammatory diseases such as autoimmune disease, inflammatory bowel disease, psoriasis, allergy, and rheumatoid arthritis. Founded in 1996, Oxagen serves customers globally, including in the United Kingdom, Russia, CIS countries, and other international markets.

Elixir Pharmaceuticals is a pharmaceutical company focused on the discovery, development and commercialization of novel pharmaceuticals for the treatment of metabolic diseases such as diabetes and obesity. The Company's scientific founders identified that interactions between specific genes and enzymes can slow the aging process, and they are developing compounds that stimulate these interactions and will be used to treat a range of diseases of aging, including metabolic disease.

Santaris Pharma A/S is a privately held clinical-stage biopharmaceutical company based in Denmark, specializing in the discovery and development of RNA-targeted therapies. Utilizing its proprietary Locked Nucleic Acid (LNA) Drug Platform and Drug Discovery Engine, the company focuses on delivering potent single-stranded LNA-based drug candidates for various disease states. Santaris Pharma's research and development efforts primarily target infectious diseases and cardiometabolic disorders, while also engaging in partnerships with major pharmaceutical companies to address a broader range of therapeutic areas, including cancer, cardiovascular disease, and rare genetic disorders. Founded in 2003, the company holds exclusive worldwide rights for the manufacture and sale of products containing LNA as an active ingredient, supporting its goal of obtaining marketing approval for its innovative therapies.

Achaogen, Inc. is a biopharmaceutical company based in South San Francisco, California, that specializes in the development and commercialization of antibacterial agents targeting multi-drug resistant (MDR) gram-negative infections. The company's primary focus is on plazomicin, which is intended for treating serious bacterial infections caused by MDR enterobacteriaceae, including carbapenem-resistant strains. Additionally, Achaogen is developing C-Scape, an orally-administered combination of clavulanate and ceftibuten aimed at addressing serious infections linked to expanded spectrum beta-lactamases producing enterobacteriaceae. Achaogen has established collaborations with various organizations, including Thermo Fisher Scientific and Ionis Pharmaceuticals, to support its drug development efforts. The company was incorporated in 2002, but faced financial difficulties, leading to a Chapter 11 bankruptcy filing in 2019, which culminated in a liquidation plan approved in 2020. All of Achaogen's revenue has been derived from government contracts for research and development within the United States.

Evotec is a drug discovery partnership firm that collaborates with pharmaceutical and biotechnology companies, academic institutions, and nonprofit organizations to advance innovative therapeutic solutions. The company specializes in a range of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. Approximately 80% of its revenue comes from shared research and development services, which involve fee-for-service work and integrated drug discovery collaborations utilizing proprietary assets. The remaining 20% of sales derive from its Just-Evotec Biologics segment, which provides contract development and manufacturing organization services for biologics. Evotec's approach emphasizes collaboration with various stakeholders, including patient advocacy groups and venture capitalists, to enhance drug discovery and development processes.

Eurobio Scientific is a French leader in the field of in vitro diagnostics, specializing in the development and commercialization of diagnostic solutions and life-science products. The company offers a diverse portfolio that includes products such as Tetanos Quick Stick, BJI InoPlex, AlloMap, and TEDAC Consortium, catering to both diagnostic and research needs. With a focus on innovation, Eurobio Scientific is dedicated to providing high-quality specialty diagnostics that support advancements in healthcare and scientific research.

Develogen is a biology-driven drug discovery company that is engaged in the development of therapies for diabetes and obesity. The company was founded in 1995 and is based in Georgia, United States.

CymaBay Therapeutics, Inc., established in 1988 and headquartered in Newark, California, is a clinical-stage biopharmaceutical company dedicated to developing therapies for liver diseases and other chronic conditions with significant unmet medical needs. Its primary focus is on seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta, currently in Phase II trials for treating primary biliary cholangitis, sclerosing cholangitis, and nonalcoholic steatohepatitis. Additionally, the company is developing MBX-2982, an orally-active G protein-coupled receptor agonist targeting gut/liver diseases, and CB-001, a preclinical-stage product candidate for treating gut/liver disease using omega-3 fatty acids. CymaBay has partnerships with Janssen Pharmaceuticals and DiaTex for developing therapies for metabolic diseases and gout, respectively.

Ardana Bioscience was created in July 2000 to commercialise research by the Medical Research Council (MRC )'s Human Reproductive Sciences Unit (HRSU) in Edinburgh, Scotland which has been at the forefront of this area of research for the last 28 years. The MRC employs nearly 100 staff at the Unit which currently receives total annual funding of £3.8 million.

CropDesign is a biotechnology company focused on delivering genetic traits for the global seed market and plant-based products. Established in 1998, the company is headquartered in Gent, Belgium, and employs over 70 professionals at its research facilities. Utilizing its proprietary TraitMill platform, CropDesign specializes in discovering and developing traits to enhance the growth and productivity of crops such as corn and rice. Additionally, the company provides plant phenotyping services aimed at improving green biomass and root development. By evaluating various plant growth regimes and screening chemicals or biologicals, CropDesign enables clients to enhance their agricultural productivity through innovative solutions. The company maintains a broad network of research and commercial partnerships to further its mission in the agricultural sector.

Epigenomics AG is a molecular diagnostics company headquartered in Berlin, Germany, specializing in the development and commercialization of blood-based diagnostic tests for cancer. The company's lead product, Epi proColon, utilizes a proprietary DNA methylation biomarker, Septin9, for the early detection of colorectal cancer. Additionally, Epigenomics offers the Hepatocellular Carcinoma Blood Test for high-risk cirrhotic patients, the Epi proLung liquid biopsy test for lung cancer, and Epi BiSKit, a pre-analytical tool for preparing bisulfite-converted DNA. The company is also focused on developing new products for the screening and diagnosis of various cancers, including bladder cancer. By leveraging unique DNA methylation patterns, Epigenomics aims to identify cancer at early stages, addressing significant medical needs in major markets such as Europe, North America, and Asia. Founded in 1998, Epigenomics is well-positioned to explore opportunities both independently and through partnerships with established diagnostics industry players.

Enanta Pharmaceuticals is a biotechnology company that discovers and develops small molecule drugs for viral infections and liver diseases. Its research targets include respiratory syncytial virus, hepatitis B virus, hepatitis C virus and nonalcoholic steatohepatitis, as well as other viral pathogens such as SARS-CoV-2 and human metapneumovirus. The company develops HCV therapies, including protease inhibitors such as glecaprevir, and collaborates with AbbVie to identify, develop, and commercialize NS3 and NS3/4A protease inhibitor compounds. Enanta was founded in 1995 and is headquartered in Watertown, Massachusetts.